Podcasts about american society

Marketing a ketamine clinic presents unique challenges that traditional medical practices simply don't encounter. High advertising costs, frequent platform bans for ketamine-related content, and the need to build trust around an innovative treatment create significant barriers that demand a strategic approach.In this episode, Kim and Sam share the exact marketing framework they presented at the 2025 American Society of Ketamine Physicians, Psychotherapists & Practitioners conference in Austin - the same strategies that helped their clinic (Reset Ketamine) dominate "ketamine near me" searches and build a thriving practice since 2018. This isn't theoretical marketing advice pulled from generic healthcare playbooks. These are proven, field-tested strategies from clinician business owners like you - who've navigated the same platform restrictions, skeptical patients, and marketing obstacles that ketamine clinic owners face daily.What You'll Gain In This Episode:・The ACC funnel framework (Awareness, Consideration, Conversion) that transforms patient acquisition・How to create organic content that acts as your clinic's "vital sign" for trust and credibility・Why newsletters are the highest ROI marketing tool for ketamine practices and how to create themEpisode 35 show notes:00:00 Teaser - Organic content as your clinic's pulse00:32 Welcome to the Ketamine Startup Podcast01:25 Understanding the Medical Marketing Funnel (ACC)04:31 Awareness: The First Layer of the Funnel06:34 Consideration: Comparing Options07:15 Conversion: Turning Interest into Action09:23 What Is Organic Content?09:57 Push vs Pull10:44 The “What To Create” Venn Diagram12:49 The Content Creation Process14:55 How Organic Content Is A Clinic's Vital Sign17:20 The Power of Newsletters26:34 Conclusion and Key TakeawaysThanks for listeningWatch the YouTube Version with Visual SlidesFollow us onLinkedinYouTubeKetamine StartUp Website

Unlock the secrets to making the most of the American Society for Horticultural Science Annual Conference with insider tips from seasoned attendees. As the 2025 New Orleans conference approaches (July 28-August 1), discover strategies that transform overwhelming events into career-defining opportunities.Veteran conference-goer Curt Rom (46 conferences and counting!) and graduate student Samson Humphrey share perspectives on navigating everything from travel logistics to networking techniques. They reveal how to leverage the conference app to build a personalized schedule, position yourself for meaningful connections at poster sessions, and deliver polished presentations that showcase your research.The conversation goes beyond academic presentations to highlight often-overlooked opportunities like resume reviews that provide one-on-one career guidance, competitions that can earn recognition and rewards, and the critical importance of informal gatherings where "the real science often happens." Whether you are presenting research, seeking career opportunities, or simply looking to expand your professional network, this episode provides actionable strategies for every conference situation. The hosts emphasize that while the science is central, it's the relationships formed over beignets at Café Du Monde or during the annual 5K Fun Run that often prove most valuable to your career.Download the ASHS conference app today, build your profile, and start planning your personalized conference experience. https://ashs.org/page/ASHSAnnualConferenceLearn more about the American Society for Horticultural Science (ASHS) at https://ashs.org/.HortTechnology, HortScience and the Journal of the American Society for Horticultural Science are all open-access and peer-reviewed journals, published by the American Society of Horticultural Science (ASHS). Find them at journals.ashs.org.Consider becoming an ASHS member at https://ashs.org/page/Becomeamember!You can also find the official webpage for Plants, People, Science at ashs.org/plantspeoplesciencepodcast, and we encourage you to send us feedback or suggestions at https://ashs.org/webinarpodcastsuggestion. Podcast transcripts are available at https://plantspeoplescience.buzzsprout.com.On LinkedIn find Sam Humphrey at linkedin.com/in/samson-humphrey. Curt Rom is at https://www.linkedin.com/in/curt-rom-611085134/. Lena Wilson is at https://www.linkedin.com/in/lena-wilson-2531a5141/. Thank you for listening! ...

We all know that clinician burnout negatively impacts the quality of patient care. That's why pharmacy residency accrediting bodies now emphasize resident well-being and professional sustainability as core components of residency training earlier in clinician careers. The American Society of Health-System Pharmacists (ASHP) Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies include a formal requirement for programs to address resilience, well-being, and burnout prevention, reflecting the increasing recognition of burnout in healthcare. Joining us to talk that out are Tony Huke, Senior Pharmacy Executive Director with Vizient Pharmacy Advisory Solutions and Kendra Gage, Inpatient Clinical Pharmacist and the PGY 1 Residency Program Director at UCHealth, University of Colorado Hospital in Aurora, Colorado.   Guest speakers:  Tony Huke, PharmD, BCPS, FASHP Senior Pharmacy Executive Director Vizient Pharmacy Advisory Solutions   Kendra Gage, PharmD, BCPS Inpatient Clinical Pharmacist PGY1 Pharmacy Residency Program Director UCHealth   Host:  Kerry Schwarz, PharmD, MPH  Senior Clinical Manager, Evidence-Based Medicine and Outcomes Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:11-03:25] What's new at the national level in terms of pharmacy resident resiliency and well-being [03:26-03:56] The intentionality of well-being in pharmacy residency programs [03:57-05:12] Examples from Kendra's program [05:13-06:40]  Program expectations to address resilience [06:41-08:33]  Assessment and potential metrics of resiliency programs [08:34-11:06]  The role of pharmacy leadership and residency program directors in resiliency [11:07-12:34] Impact of resiliency programs so far   Links | Resources: Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Shadd Maruna is Head of the Department of Sociology, Social Policy & Criminology at the University of Liverpool. His research focuses on how individuals desist from crime and reintegrate into society, emphasizing the transformative power of identity and narrative. Shadd's influential book, Making Good, introduced the concept of the “redemption script,” reshaping our understanding of desistance. He served as President of the American Society of Criminology in 2023.

Mike Sager is an American author, journalist, and educator.A former Washington Post staff writer, Rolling Stone contributing editor, and writer at large for GQ, Sager has been a contributing writer for Esquire for more than three decades. In 2010 he received the American Society of Magazine Editors' National Magazine award for profile writing for his story "The Man Who Never Was," which appeared in Esquire. He is the author of more than a dozen books, and has served as an editor on several journalism text books. Sager has read and lectured at American schools of journalism. In 2012 he founded The Sager Group LLC, a content brand with a variety of functions ranging from publishing to film making, to general marketing.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-opperman-report--1198501/support.

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on. In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology. AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class—one that could herald “a new era” of cancer treatment beyond traditional chemotherapy. To learn more about the topics in this episode: AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop See omnystudio.com/listener for privacy information.

“United States soybean seed protein concentrations – current status, challenges and some potential crop management solutions” with Dr. Anuj Chiluwal. Soybeans are a crucial crop in the United States for a variety of uses, including for its use as a protein source in animal feed. However, in recent years, high yield varieties have seen a steady decline in seed protein concentration. In this episode, Anuj joins me to discuss the sources of this decline and some potential strategies to combat it. Tune in to learn: ·         Why soybean seed protein is declining in US soybean ·         How the US may be a template for other countries with similar problems ·         What temporary solutions may be available for this problem ·         Which future research paths may bring about more sustainable solutions If you would like more information about this topic, this episode's paper is available here: https://doi.org/10.1002/agj2.21731 This paper is always freely available. Contact us at podcast@sciencesocieties.org or on Twitter @FieldLabEarth if you have comments, questions, or suggestions for show topics, and if you want more content like this don't forget to subscribe. If you'd like to see old episodes or sign up for our newsletter, you can do so here: https://fieldlabearth.libsyn.com/. If you would like to reach out to Anuj, you can find him here: anuj.chiluwal@kysu.edu https://www.kysu.edu/directory/faculty-staff/anuj-chiluwal.php https://www.linkedin.com/in/anuj-chiluwal/ Resources CEU Quiz: Coming soon Transcripts: https://www.rev.com/app/captions/Njg1MWI0MjE2MDAzODViYzNhZjVkNjYzWE4wOEZYc1pLNHNQ/o/Q1AwMTA4NTk3MzE4 “Soybean management for seed composition: The perspective of U.S. farmers” paper: https://doi.org/10.1002/agj2.21082 “Exploring Nitrogen Limitation for Historical and Modern Soybean Genotypes” paper: https://doi.org/10.2134/agronj2018.04.0271 “Quantification of Soybean Leaf Senescence and Maturation as Impacted by Soil- and Foliar-Applied Nitrogen” paper: https://doi.org/10.2134/cftm2018.07.0051 “Probability of Yield Response to Inoculants in Fields with a History of Soybean” paper: https://doi.org/10.2135/cropsci2009.04.0185 “Late-Season Nitrogen Applications Increase Soybean Yield and Seed Protein Concentration” paper: https://doi.org/10.3389/fpls.2021.715940 “Is soybean yield limited by nitrogen supply?” paper: https://doi.org/10.1016/j.fcr.2017.08.009 “Assessing Variation in US Soybean Seed Composition (Protein and Oil)” paper: https://doi.org/10.3389/fpls.2019.00298 “Regional analysis of planting date and cultivar maturity recommendations that improve soybean oil yield and meal protein concentration” paper: https://doi.org/10.3389/fpls.2022.954111 Extension fact sheet: https://www.kysu.edu/documents/college-of-agriculture-communities-the-sciences/2025-Fact%20Sheet%20Soybean%20Seed%20Quality.pdf University of Minnesota annual soybean quality reports: https://extension.umn.edu/soybean/soybean-seed-quality Thank you to our volunteer Om Prakash Ghimire for help with the shownotes and other assets. Thank you to Cole Shalk from 12twelve Media for the Audio Processing on today's episode. Field, Lab, Earth is Copyrighted by the American Society of Agronomy, Crop Science Society of America, and Soil Science Society of America.

In the 94th episode of the WGI Unleashed podcast, we're excited to introduce you to Chris Velasquez, EIT, a Senior Graduate Engineer in our Civil + Land Development Team based out of WGI's San Antonio, TX office! Join us as hosts Dan and Katie travel to the Alamo City to sit down with Chris for a spirited, insightful, and entertaining conversation filled with compelling career highlights, hilarious anecdotes, and fascinating behind-the-scenes stories from Chris's unique journey within the architecture, engineering, and construction (AEC) industry. From Curiosity to Engineering Excellence Chris's passion for engineering and innovation sparked long before his professional career began, and his journey to where he is today is anything but conventional. Born in New Jersey but raised in Rosenberg, Texas, Chris humorously recounts his childhood experiences growing up in a quiet subdivision, jokingly referring to it as "the hood." His curiosity and keen problem-solving abilities were evident from a young age. On the podcast, Chris shares vivid memories of his school years, including an unusual educational structure where sixth, seventh, and eighth grades each had their own separate buildings, and his early fascination with engineering, sparked by hands-on high school classes in aerospace, mechanical, and civil engineering. College Triumphs and Steel Bridge Competitions Chris chose to attend the University of Texas at San Antonio (UTSA), balancing the desire for independence with proximity to family. At UTSA, Chris actively participated in the American Society of Civil Engineers' Steel Bridge Competition, where his team repeatedly secured regional wins and competed nationally against some of the most prestigious universities in the country! Internship Experiences and Transition to WGI Chris gained valuable experience through internships, initially exploring public works before discovering WGI through a UTSA career fair. His humorous anecdote about initially confusing WGI with a color guard organization highlights his amicable personality and underscores his seamless fit within WGI's culture. His internship at WGI proved instrumental, smoothly transitioning him into a full-time role upon graduation, thanks to the mentorship of colleagues in the public works team. From Intern to Influencer Over four years at WGI, Chris has grown from an eager intern to a respected Senior Graduate Engineer. He reflects on his professional development, noting how he now actively mentors new team members and interns. Chris highlights how each project presents unique challenges, making every day exciting and engaging. He emphasizes how teamwork and a supportive environment have significantly contributed to his personal and professional growth at WGI. Life Beyond The Office Outside work, Chris enthusiastically shares his love for chicken wings, especially lemon pepper wings cooked in an air fryer, proudly noting his dislike of chicken nuggets. He also humorously recounts the San Antonio office tradition of participating in the "Hot Ones" spicy wings challenge, despite his aversion to spicy foods, simply because he "doesn't like giving up." What Makes WGI Special Chris quickly points out that what makes WGI stand out is its remarkable people and collaborative spirit. "At WGI, you're more than just an employee - you're part of a close-knit community genuinely invested in your growth and success," Chris shares, emphasizing the nurturing and supportive company culture that inspires everyone to reach their highest potential. Tune In This episode is packed with unforgettable moments - from conquering UTSA's Steel Bridge competitions and navigating spicy wing challenges in the San Antonio office, to mentoring the next generation of engineers and solving real-world infrastructure problems with heart and humor. So, tune in, and as always, stay curious, stay driven, and keep unleashing your full potential! Visit your favorite podcast app now and subscribe to WGI Unleashed to receive alerts every time a new episode drops. You can find us on Spotify, Apple Podcasts, iHeart Radio, or wherever you find your favorite podcasts.

For decades, the U.S. has prioritized the four-year degree path, but millions of workers thrive through alternative routes. In this episode, Kyle Hayes, Senior Director of Public Policy at the American Society of Association Executives (ASAE), joins host Jason Altmire to discuss how one bipartisan proposal could fundamentally change workforce preparation. The Freedom to Invest in Tomorrow's Workforce Act would allow families to use 529 Savings Plans to fund short-term credentials, career training, and workforce development programs. With strong bipartisan support and minimal federal cost, this policy shift could be the key to unlocking more affordable, practical education pathways for millions.To learn more about Career Education Colleges & Universities, visit our website.

Did you know that one 20-ounce soda can pack more sugar than five donuts—and still leave you hungry? In this episode, I unpacked the deceptively sweet world of sugar-sweetened beverages from sodas and sweet teas to fruit juices and even those “healthy” smoothies. I busted eight common myths that might be sabotaging your wellness journey without you even realizing it. We talked about how liquid calories sneak past your hunger cues, spike blood sugar, fuel cravings, and trigger fat storage. I broke down why fruit juice isn't the same as whole fruit, why diet sodas and energy drinks aren't a free pass, and why even your favorite boba tea might be more dessert than drink. So whether you're sipping flavored coffee or reaching for coconut water, it's time to start reading those labels. My challenge to you? Swap one sugary drink a day for water or an unsweetened alternative, your body will thank you for it. Ready to take control of your cravings, boost your energy, and finally see results on the scale? Tune in now to uncover the hidden truths about sweetened drinks and start making smarter choices that truly support your health goals!   Episode Highlights: The hidden impact of sugar-sweetened beverages on weight gain and metabolic health Why liquid calories don't satisfy hunger and often lead to overeating Eight common myths about sweet drinks—busted with science The truth about fruit juice, diet sodas, smoothies, and boba tea How sweet drinks spike blood sugar, insulin, and fat storage Smarter alternatives to hydrate without sabotaging your health Practical tips to reduce sweet drink intake and improve energy, mood, and weight loss Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

On this episode, we are joined by Kimberly Masker, an occupational therapist and certified hand therapy, and Tauni Bird, also an occupational therapist who have been researching and educating others on treating patients in the context of substance use. They share with us what substance use disorder is, the stigma that surrounds these patients, and what we as hand therapists can do to mitigate that stigma and provide harm reduction. Welcome to Hands in Motion, Kim and Tauni.Guest bio: Kimberly Masker, OTD, OTR/L, CHT received her undergraduate degree from ETSU in 1995, her Master's in OT degree from Washington University in 2000, and received her post-professional doctorate in OT from Rocky Mountain University of Health Professions (RMUoHP) in 2015. She earned her Certified Hand Therapist (CHT) specialty certification in 2007. She is an assistant professor in the Doctor of Occupational Therapy Program at East Tennessee State University. Kim's clinical practice is as senior therapist at The Hand Center at Bristol Regional Medical Center in Tennessee. Her professional interests have focused on hypermobility, wound care, upper extremity multi-trauma, substance use disorders and stigma, and treatment of musicians. She enjoys writing for various hand therapy related publications and blogs. She serves as a consultant for Axogen on studies such as pain and peripheral nerve injuries. She currently serves as Secretary Treasurer of the Northeast District of the Tennessee Occupational Therapy Association. She has volunteered for many years with the American Society of Hand Therapists (ASHT), is co-editor of the 4th edition of the CHT Test Prep Book and Clinical Reference (2022), and is the current President of ASHT.Tauni Bird, OTD, OTR/L (she/her) is an occupational therapist and hand and upper extremity therapist. She is a member of the American Society of Hand Therapists, American Association for Hand Surgery, and American Occupational Therapy Association. She is interested in harm reduction and health equity. Her work on these topics includes conference presentations, non-research articles, and special grant projects. The views and opinions expressed in the Hands in Motion podcast are those of the guests and do not necessarily reflect the official policy or position of ASHT. Appearance on the podcast does not imply endorsement of any products, services or viewpoints discussed.

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

Join Elevated GP: www.theelevatedgp.com Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Dr. Margeas was recently named on the 2024 "32 Most Influential People in Dentistry" by Incisal Edge Magazine. Click here to learn more! Dr. Margeas graduated from the University of Iowa College of Dentistry in 1986 and completed his AEGD residency the following year. He is currently an adjunct professor in the department of Operative Dentistry at the University of Iowa. He is Board Certified by the American Board of Operative Dentistry. He is a Diplomate of the American Board of Aesthetic Dentistry, a Fellow of the Academy of General Dentistry, American Society for Dental Aesthetics and International Team of Oral implantologists (ITI). He has written numerous articles on esthetic and implant dentistry, and lectures and presents hands-on courses nationally and internationally on those subjects. He is currently the Editor in Chief of Inside Dentistry, on the Editorial Board of Compendium, and is a contributing editor to Oral Health in Canada. His memberships include OKU Honor Dental Society, American Academy of Esthetic Dentistry, and the American Academy of Restorative Dentistry. Dr. Margeas maintains a full-time private practice focusing on comprehensive restorative and implant dentistry in Des Moines, Iowa.

Today we're exploring a concept that has deep roots in process safety and infrastructure management, but also has meaningful applications in electronics manufacturing: Damage Mechanism Reviews, or DMRs.My guest today is Dheeraj Narang, a corrosion and reliability engineering specialist, process safety activist, and digital innovation researcher with an impressive track record across the energy sector.Dheeraj has spent his career developing and implementing asset integrity programs for more than nine global energy companies across the U.S., India, and the Middle East.He's also a visionary advocate for using advanced technologies, industry best practices, and safety standards to uplift regions and workers where such systems are still under development. Whether it's through his service on global conference committees or his contributions to cutting-edge digital initiatives, Dheeraj is on a mission to blend technology, safety, and human rights into a unified vision of operational excellence.In this episode, we'll discuss:What Damage Mechanism Reviews are and why they matter.How DMRs tie into reliability programs like FMECA.How DMR thinking could benefit industries outside of oil and gas—including electronics manufacturingand how emerging technologies like AI and machine learning can amplify the impact of these reviews.Whether you're in energy, electronics, or any industry where reliability and safety are paramount, this is a conversation you won't want to miss.Dheeraj's Contact Info:dnarang1@my.harrisburgu.eduReferences:Narang, D. Dual Benefits of Damage Mechanism Reviews. 2024 AiCHE Spring Meeting and 20th Global Congress on Process Safety, New Orleans, LA, March 25-27, 2024.Narang, D. Application of FMECA Methodology in Reliability Assessment of Complex Assets in Process Plant Industries. Reliability, Maintenance & Managing Risk Conference (RMMR) by American Society of Quality (ASQ), Pittsburgh-PA, July 25-26, 2024.Narang, D. Feature Selection Methodology for Developing a Supervised Machine Learning Model for Risk Based Inspection Study on Process Plant Assets. 79th Instrumentation and Automation Symposium, Mary Kay O'Connor Safety & Risk Conference, College Station-TX, October 22-24, 2024.Narang, D. Application of Machine Learning Concepts in Inspection Data Management System at Process Plant Facilities. 27th Process Safety International Symposium, Mary Kay O'Connor Safety & Risk Conference, College Station-TX, October 22-24, 2024.

Maria Artunduaga is the founder & CEO of Samay, the winner of the 2024 MedTech Innovator accelerator, as well as a groundbreaking physician, scientist, and inventor. Maria discusses her inspiring journey from a small town in Columbia to leading a top MedTech company in the US. After pivoting away from plastic surgery training, she channeled her efforts into creating Sylvee, an AI wearable sensor for COPD patients. Maria shares her relentless determination, innovative problem-solving strategies, and the creation of a company culture that emphasizes learning and diversity.    Guest links: https://www.samayhealth.com/home | https://www.linkedin.com/in/drartunduaga/  Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 057 - Maria Artunduaga [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and I am delighted to welcome as my guest today, Maria Artunduaga. Maria is a physician, scientist, and inventor with 60 plus prizes, including becoming the first woman to lead a US LATAM company to win MedTech Innovator, the world's most competitive accelerator for medical technology surpassing over 1300 global companies. A top 1% student in Columbia, her country of birth, she relocated to the US to pursue plastic surgery training, but abandoned it to dedicate herself to solve the problem that killed her grandmother-- a lack of home technologies that can detect COPD exasperations early. Maria has raised 5.2 million, almost 60% in non-dilutive capital from NSF and NIH to build Sylvee, an AI wearable sensor that can provide COPD patients with continuous data on pulmonary functions similar to what continuous glucose monitoring sensors do for diabetic patients. Her invention has been featured by a hundred plus media outlets, including Forbes, TechCrunch, Bloomberg, Fierce Healthcare, and more. Before Samay, Maria completed postdoctoral studies in human genetics at Harvard Medical School, started a plastic surgery residency at the University of Chicago, and completed two master's degrees, one in global public health at the University of Washington, and another in translational medicine at the University of California at Berkeley and San Francisco. She lives in Mountain View, California with her husband, 2-year-old daughter, and four pets. In her free time, she enjoys flamenco dancing, bolero singing, traveling the world, and fostering diversity in and outside the workplace by mentoring underrepresented scientists and entrepreneurs. All right. Well, thank you so much for being here, Maria. I'm so excited to finally get a chance to speak with you. I'd love if you would share a little bit about your background and your career trajectory. What led you to MedTech? [00:02:40] Maria Artunduaga: Sure. So it's gonna be a little long and I'm gonna tell you everything about my life because the personal history is very important to me and for my company too. So, as you have noticed, I have an accent. So, I grew up in Columbia in a very small town in the southern part of the country. My parents were both doctors and I'm the oldest of four kids and two of us followed their lead. So my life in my city was pretty chill. Everyone knew everyone. I spent most of my days at a Catholic school studying very hard on weekends where I usually spent tagging along my parents to doctor events. One of the things that I really like to tell, it's how my parents work as entrepreneurs really shaped my life. They were real pioneers. They built in my hometown the first big clinic back in the eighties and the nineties. And my mom was the only woman in that group, and she actually was the CEO for a while, which was a big deal. She was the only woman in a partnership of 10 people. And watching them build that clinic, that hospital really taught me a lot about dealing with uncertainty and finding solutions. Every day we'll have supper or lunch and I'll just hear all of these challenges and stories, their struggles and how they solve things. Something that was, that is definitely super helpful in what I do now, right? So, and then I was 16 and after high school I moved to Bogota, the capital, which is up in the mountains, it's very cold. I got a scholarship 'cause I was always a very good student. You know, career I spent my last year, I spent nine months in the US. Honestly, coming to the US blew my mind. The technology that I got to see, the speed, effects on science, it was nothing like I've ever seen before, and that was true inspiration for me. So I knew that I had to come to the US. I needed to come back to learn from the best, of course. And it's interesting because my parents didn't want me to relocate to the US. I was the oldest. I was supposed to follow into their footsteps and obviously, like inherited that clinic, right? That hospital, we call it clinic, it's actually a hospital. And I was a very contrarian. I didn't listen to them. I told them, you know, I really wanna be where the best people are. And what I did was that I, it took me three years to save the money to come to the US, to get Harvard to actually sponsor me my visa because they wouldn't pay me for the first year. So I remember I had to save $30,000, which in pesos is significant. So back in 2007, so many years ago, I made it to Boston, and the original idea was that I wanted to become a pediatric plastic surgeon and bring that level of care back to Columbia. I spent four years of researching a genetic ear condition that's called microtia. And with that work, I was able to land a plastic surgery residency spot or position at the University of Chicago. And I shared this with a lot of people. I actually had a really negative experience. Things didn't go as planned. I actually faced discrimination. I eventually, you know, had to leave and I made the top choice to never ever go back into clinical practice. And I changed paths. I was 32 years old and yeah I decided to switch gears. I retrained into public health and tech. And then in 2016, I moved to the Bay Area where I am right now. And I got another scholarship to finish master's in translational medicine at UC Berkeley and UCSF. And during the courses that I took, some of them with business class etc., etc., I decided to found Samay in 2018. I really wanted to build something that would really make a difference in respiratory medicine. And this is where my grandmother comes. So my, the grandmother, my abuela, her name was Sylvia and she had Chronic Obstruct Pulmonary Disease or COPD and she's the reason behind my company. So, she often couldn't tell when her symptoms were getting worse. That's a huge problem. Catching the respiratory attacks, exacerbations is definitely key to keeping people outside of the hospitals, and obviously feeling their best to have a better quality of life. So, that's what we are trying to solve with a company, right? If we are able to catch those exacerbations even with a day or two notice in advance, right, that we can all make a difference. And so by missing these exacerbations, we are having really high expenses in hospitalizations and ER visits and the problem we trying to solve is that today technologies that are adequate enough to be used outside of the hospital because the ones that are considered to be the gold standard, they are very expensive. They are confined to their hospitals and they are very difficult to complete for the patient, especially when they're exacerbating. They need to blow out forcefully for about 10 seconds, 21 times. So what we are doing is, we are developing a sensor that makes it super simple for people to use it at home to track their lung function without doing those forceful maneuvers and ideally in the future to warm them, right? Like to let them know when things are starting to go south or obviously, you know, not going very well, and that's what it's all about. I mean, that's what we do with Sylvee right here. And it's wearable sensor and we have done significantly well over the past couple of years. We actually just won MedTech Innovator. [00:08:04] Lindsey Dinneen: Yeah. Significantly well over the last few years. Yes. So congratulations on that, and I want to dive into all of those exciting milestones in just a second. But I am, first of all, so inspired by your story. Thank you for just sharing that your resilience and your grit and your determination are really admirable. So thank you for sticking with something that was not easy, not an easy path. [00:08:29] Maria Artunduaga: I know. I know. [00:08:31] Lindsey Dinneen: It continues not to be, ironically, as we've kind of touched on before, but just going backward a little bit in your story. So I, it sounds to me like getting the opportunity to watch your parents have this incredible impact on their community and the healthcare and the opportunity is just so valuable for you. And even just learning about how your mom was the CEO and those kinds of things, did that help shape the idea for you that not only is entrepreneurship possible, is innovation and healthcare possible, but you can also be this in incredible leader as a woman in whatever capacity? I would just love to dive into that. [00:09:13] Maria Artunduaga: Yeah, it's super interesting, right? My mom really taught me a lot about leadership. She's a surgeon, so you can imagine how good of a leader she is in the operating room at home, everywhere, right? I mean, she's definitely the general, that's how I call her. And I honestly, I try to replicate, so my leadership and styles pretty much shaped by her. So I always call her my best role model whenever somebody asks me about the question, right? So I'm just like her. I lead from the front. I like setting the pace by working the hardest. So I really like to lead by example and I also, just like she did, and obviously because of her surgical training, I hold myself to a really high standard, and I expect everyone on my team to do the same. So people in my company know that I'm very strict, I'm very disciplined, and they know that from the beginning. It's so funny because when I interview all of them, at the final interviews with me, and I actually do the anti sale to join Samay. It's like, this is, these are all the reasons why you shouldn't join. I start describing myself as a very intense, obsessed CEO with insomnia, which I still have, because I really wanna make this work, right? So, yeah, I, ask them, and most of them say yes. I really like, I attract people that like challenges, especially intellectual challenges. So, yeah, to this point, most of them say yes. Some of them have obviously, you know, because probably too much. But at the same time, I tell them, "Look, this is going to be very hard in terms of the deliverables, the things that we're expecting from you." But at the same time, my goal is to not only help people with respiratory problems, I try to sell the company as a company where everyone that gets hired can be themselves and thrive. So, so for example, I tell them," Look, I'm trying to be the boss that I never had." And this goes obviously very tied to the very negative experience that I had during my surgical residency and even before, right? So, I never had a boss that really supported me, who recognize my true self and those characteristics as good things, right? So they always try to tone me down. I'm very energetic, as you can notice, and I'm also super ambitious. I'm really ambitious. I wanna do all of these great things. And they always thought that I was aiming for too much, especially for a woman. It's like, " You need to lean in, Maria. You need to behave." So I remember my residency, they were criticizing like, "Why are you behaving like this, Maria? Why are you asking so many questions? You're asking too many questions. You look more as an internal medicine doctor. Why are you always smiling, Maria? Why are you so happy?" So now, with everyone that I hire, what I try to do is that I focus on understanding their dreams and I try to figure out how this job is gonna help them get there. So if they wanna become a top engineer, maybe they wanna learn managerial skills, or they wanna run operations, or they eventually wanna become a founder themselves. So I try to create a partnership with them where they obviously help me succeed with the company, build Samay, but at the same time they get to do this personal growth. So it's extremely important that they get to place where they wanna be. [00:12:32] Lindsey Dinneen: Yeah, that's wonderful. And such a gift to your employees. And I also honestly, that sort of anti interview or whatever technique is brilliant because you do want it to be a fit for everyone, and it's so much better to have aligned expectations from the start. So, oh my goodness, that's so interesting. So, okay, so then. Speaking into that, how do you develop a company culture for yourself? You've learned from some pretty negative experiences, so obviously that's what not to do, but you know, as you're crafting your own company culture now, what kinds of things are sort of your core values, other than of course, your hard work and your excellence and holding yourself and others to high standards, but what kinds of things do have you developed that make it special to be where you are? [00:13:19] Maria Artunduaga: Yeah, I mean, that's a really good question. I'm very true to myself, and one of the things that I wanna do with Samay, it's I wanna create legacy. If you go to my WhatsApp, that's exactly the little logo or the slogan that's below my name: I'm creating or building my life's legacy. That's how I pitch myself. So I really wanna be remembered as someone that made healthcare more accessible, especially for the people that get left behind. So growing up in Columbia, I saw firsthand how unfair things will be and I wanted to change that. So that's how the values of Samay go, people first. I think legacy, it's extremely important, right? It's about getting those life changing tools and opportunities into the hands of people who really need them. And again, it's not necessarily, the group that we're building. It's the own experience of building a company with me, learning from the company, from the people that are working with. I really wanna make it accessible for people. And I wanna also be obviously a source of inspiration. You don't necessarily need to be this perfect person to be a CEO. You know, life is a struggle and that's totally fine. Just be very passionate about building legacy, right, your work and how you're impacting other people. And especially for me, I do a lot of work with women and minorities. I really wanna empower them to chase their dreams in science and technology. I really care about people. I don't know, I'm selfless about me. It's all about the others and creating legacy and being remembered. So, yeah, that's how I, that's how I roll. [00:14:59] Lindsey Dinneen: I love that. I love that. So speaking of you embracing the CEO role, when you first started your company, did you feel ready to step into this kind of position? Or was it something where you just were like, "You know what? I see the need. I know I can make a difference in this field. I'm gonna do it and I'll learn along the way." [00:15:19] Maria Artunduaga: No, not at all. And let, so there's a very good anecdote that I'm sharing. Again, back to all of these life changing experiences. I got into medtech because of, I don't know, somehow the planets got aligned, right? So I was doing a master's in public health because I thought that was going to be my real call, working for Gates in Seattle, because that's where I actually lived for about two years. Then I came to realize that it was very bureaucratic. It's very, was very slow. I have a type A personality. I really like to fix things very quick. I like to implement stuff. So I decided to do a second master's degree, and as I mentioned, here in Berkeley, I decided to join one of Atma METs minority programs for students, right? It's called SMDP. And I remember that was back in 2016, and they sent me to Minneapolis for the big conference. And that's where I got my first real taste of MedTech. And I remember watching the MedTech Innovator finals with Paul Grand. He was introducing the program, the finalist. I remember clearly seeing all of his pitches and how Green Sun Medical CEO won, and it was a game changer to me because when I saw them pitch, it was very exciting. You know, all these technologies, the many millions of people they could definitely impact, I saw that, and it clicked. I could turn the scientific ideas into something that helps millions in a way, the way how I would practice medicine, but in a more impactful way. So interesting story though. So the other thing that was very inspiring or at least that motivated me, I was the only person in the room who looked like me and spoke with an accent from South America, from Latin America. So it was like two reasons behind it. For me, it was I wanna be a medtech entrepreneur, but at the same time I wanna be able to break the glass ceiling, right? The first Latina physician CEO building a company that has hardware, software, and AI, this is what we actually do. And yeah, so it, it's mainly that. I really like challenges and I'm very motivated to show people that I can do things that might seem impossible or too difficult. So I really like showing people that anything is possible with a lot of hard work and determination. So yeah, that's mainly it. [00:17:47] Lindsey Dinneen: I love that. Embracing those challenges, running full steam at them and having that, I don't know, that gumption is fantastic too. And the desire, like... [00:17:57] Maria Artunduaga: Thank you. [00:17:57] Lindsey Dinneen: ...you said, to break through those ceilings and to represent and say, "No, it is possible." It is, and I love that. So, excellent. Okay, so can you share a little bit about the journey that the company has gone under recently and some of the really exciting milestones? I know there have been bumps and whatnot, but maybe some of the exciting things that have been developing and what you're looking forward to as you continue down the road. [00:18:24] Maria Artunduaga: Sure. I mean, whew. There are so many things that have been happening for the last couple of months. So it's been a long journey. It's been six years so far. Initially, you know, I wanted to build a company with an idea that was inspired, obviously, by the fact that I lost my grandmother to exacerbation and also because, at the time, I didn't know what I wanted to build. When I was doing an interview with a pulmonologist, what I realized was that I could actually build a technology that could be inspired by consumer devices, so hearing aids for example. And funny story is that my husband who is also Columbian, and went to MIT, he's been working at Google for over a decade and he's an auto engineer. He does a lot of things. He's very smart and he's one of the main architects. What I decided to do back then was, let's repurpose hearing aid technology by sending signals through the chest, and let's use the physical principle of acoustic resonance to understand what's going on inside of the lungs. And that's exactly what we are doing. We have 10 granted patents so far. We have 20 more pending on pulmonary so far. So we've done a lot of things. So we've tested that device on 450 people almost. All of our numbers of accuracy are over 90. Sensitivities and specificities are also between 82 to 98. Right now we are starting to see changes a few days before an exacerbation is actually diagnosed by a physician, which is extremely exciting. We have data from two people. Obviously it's a small sample size. We are following eight of them, and we're aiming to finish at 60 to hundred people in the next year or so. So that's our main goal. We've raised 5.2 million, 60% of that money is coming from grants, federal grants, and we just submitted a breakthrough designation to the FDA about a week ago, so fingers crossed, though, we get it right? There are a lot of things in the pipeline, things that are very exciting. Right now I'm super excited 'cause those six years were very hard. I was running a science project with my nails, getting money from grants, help from people who have known me forever. It was very hard for me to recruit a full-time CTO. So my husband has been helping me with some hours here and there. And we have right now 12 people in Columbia. So for developers, designers, clinical researchers, we are running most of our operations in Latin America because it's extremely, well, obviously cost efficient, and more importantly, we have access to people that are patients especially that are, that exacerbate more often. So we are to leverage all the different angles that we can get. [00:21:04] Lindsey Dinneen: Yeah. Wow. So lots of exciting things in the works and in the future, and oh my goodness, I'm so excited, can't wait to continue to celebrate all those wonderful accomplishments. So I'm curious, as you've taken this journey and even before with your other health experiences and finding this path, are there any moments all along the journey that really stand out to you as affirming, "Yes, I am in the right place at the right time, in the right industry." [00:21:31] Maria Artunduaga: Yeah, beyond the MedTech Innovator, the experience eight years ago, I mean, every day I find that this is the perfect fit for me. I always tell people, "Look, entrepreneurship is not for everyone. It really needs to be a fit of personality." So when I talked to my parents, because at the beginning they weren't very agreeable with the idea of me becoming an entrepreneur 'cause physicians don't do this, right? I was sort of like a black sheep of a family, 'cause my sister, she's successful and she's a pediatric radiologist as she's working for an academic center in, in Dallas. So, my personality, I'm Type A. I'm very anxious. I really like doing things super fast. I really like to get things done, right? So, I dunno if I picked the wrong career, probably could have done a better job as an engineer, as a scientist myself. So at heart, I'm a true scientist. That's what I really enjoy. I like practicing medicine, sort of miss it a little bit, but I'm more in the quest of solving questions and discovering, right? That's what really excites me. And then, every day is a new day when you're building a company. And the challenges that I have every day, all of the problems I have to solve, I really enjoy the process of solving them. And this is a little crazy. Who gets excited with problems, right? So, I don't know, that's probably me. So I guess every day, the moment I go home or that I go to sleep, I say, "This is perfect. I don't think I'll be as happy as I am right now if I had stayed medicine. I don't think so." [00:23:10] Lindsey Dinneen: Wow. And that says a lot. And that just affirms to you on a daily basis, "Yeah. I am doing what I'm supposed to be doing. That's wonderful. [00:23:17] Maria Artunduaga: Exactly. Right. It's like, yeah, I'm good at this thing. You know? I like solving problems. I got, I really enjoy the fires. I really like them. I's like, I don't know. I'm, yeah. I'm addicted to them. [00:23:30] Lindsey Dinneen: I love that. Well, and that is unusual, and I'm curious, do you? But it's a great thing. No, it's a wonderful thing. Yeah, no, absolutely. I love that. So, so when you're at finding yourself up against a problem, do you start with any particular kind of established framework? Do you like to just brainstorm solutions? How do you approach problem solving? [00:23:53] Maria Artunduaga: Gosh, this is a really good question. It's like, you know, if I had to teach something, right? So I'm very good at solving problems, at connecting different disciplines, right, to solve those issues. So for example, the way how I go about them, first of all, I don't get frustrated or too anxious about it. I always try to think first, right? And then, yeah, I start brainstorming. I'm very quick at thinking, my mind goes super quick. I have a whiteboard right behind me. I do a lot brainstorming on my own. I ask a lot of questions too. So I rely on a lot of people, and I get a lot of feedback on the way, how I think a problem needs to be solved. And obviously with time and experience, the older that you get, the better you become, right? So yeah, honestly, every problem is different. I just like seeing it from different angles, right? I'm very good with social stuff. I'm very good with arts too. I really like doing science, learning a about engineering. I really like different ways of solving problems. For example, I remember that I we had this NIH grant and we were working collaboration with a big, famous academic center right here. And things weren't working very well. That was through during a pandemic and I was getting charged things that we actually didn't approve. So things were getting a little awkward. I decided to finalize that agreement. But then I got through this situation that I had no access to patients here in the States, and at the time, I didn't have my clinical site in Columbia opened up. So what I did was the craziest thing, which is what I did, was that I bought an $80,000 machine and I came into an agreement with a friend from medical school who has a pulmonary practice in South Florida, one of the largest pulmonary practices. He's a partner with nine other guys, and they see probably a hundred patients every day. Can you imagine that? So respiratory patients, and I told him, "Look, I don't have any money to pay your rent, but I'm gonna give you equity for that rent, and you're gonna use this machine from Monday through Thursday, and I'm going to test your patients from Friday to Saturday. And I'm going to bring people, I'm going to become my own CRO, right? So I'm gonna bring people, doctors, from Columbia on a J1 visa as a research scholar visa. I'm gonna train them and I'm gonna get them to do the recruitment, review everything, test the patients. We are going to become our own CROs, and we are going to do as many people as we can every single week." So we were able to do 430 people in a span of a probably a year and a half. Something that usually would cost us thousands of dollars. I dunno how much money I spend, probably just 300,000 to do everything. Can you imagine? I mean, that's significantly cheap compared to any other quote that I've been getting from an academic center. So, I sometimes go for the crazy idea, right? Like, what's the craziest thing that I could think of? I literally, I write it down, right? And then I just try to double check with my lawyer. "Am I doing something illegal here?" And I, yeah, I cross reference with other founders. " I'm thinking of doing this, how that's that sound?" And they're like, "This is pretty non-traditional, Maria, but I mean, if you can get it done..." I'm like, "Yeah, of course I can get it done." And I just get it done. I just don't take a no for an answer. I'm very good at also finding, convincing people to jump on board with the vision, the mission. This excitement, this energy, people really get very engaged with Samay and with me as a founder, and they love it. Most of these people either have invested in the company, they are helping me many more hours, pro bono, literally free, and we are building together. [00:27:43] Lindsey Dinneen: Wow, that is so cool. And what a fantastic story. Thank you for sharing that one as well. Oh my word. [00:27:50] Maria Artunduaga: I have way too many stories to share. This is the one I really like to, to tell people. [00:27:55] Lindsey Dinneen: I love that, and I love the willingness to come up with those crazy ideas. And it might be just so crazy that it works. So, hey, you never know until you try, and that's fantastic. Oh my gosh, I love that approach. Alright, so pivoting the conversation a little bit just for fun. Imagine you are to be offered a million dollars to teach a masterclass... I know! ...to teach a masterclass on anything you want. What would you choose to teach? [00:28:22] Maria Artunduaga: Yeah. So, good question. So, gosh, I, I tackle problem. So my, my brain again is very good at figuring stuff out. That plus the fact that I'm very stubborn. So if I'm into something, I don't give up easily. And now I'm gonna tell the story about our winning MedTech Innovator. We beat 65 companies globally, right? And I still like, sort of, I cannot process that we won. So the story goes like this, but a year ago, I tried to raise five millions, my very first institutional round, and I totally flopped. [00:28:55] Lindsey Dinneen: Oh. [00:28:56] Maria Artunduaga: I only got $200,000 because multiple funds that I was talking to, they wanted me to feel half of the round before weighing any money or signing anything. So you can imagine. So do I got, you know, chicken or the egg problem? I failed. And instead of crying or mopping, I thought, "Okay, wait. I got into Medtech Innovator. You know what? I'm just gonna win that competition, still $350,000." And why not? So obviously people, my advisors, my best friend, "Like, you're crazy. It's the most competitive thing ever. You're not established in the field. People know who you are, but it's not like you have exited a company or anything, right? You're not even an engineer, Maria." So what I did was, again I went back to my whiteboard. Again, I probably should have become an engineer before, I dunno. I'm really good at solving problems. So I was like, "You know, this is a problem. These are the different ways how I can tackle this." And more importantly, I'm very good at the studying stuff. I really like, again, knowing, wisdom, information. I just love that. I really love that. So what I did was, I treat it like a big project, and I talked to the past winners, anyone who had done or won any sort of like prize with MedTech Innovator, and I figure out their secret sauce. So I either talk to them, I studied every single video, every single pitch. I spend many hours studying everyone who had one or had done significantly well throughout the accelerator. So what I discovered was the accelerator was kind of a school, like a school. So the harder you work, the better you do. And one of the things that I realized was that mentors and reviewers were key players. So I focused on building those connections. I met with many of them. I probably spent about, I don't know, probably four to five hours meeting with mentors, anyone who I thought could help me somehow, obviously, for free, because a lot of the help that they give used for free. And I also spent a lot of time doing homework, the webinars, et cetera, et cetera. I ask a lot of people for advice. I really got people excited about Samay. I recruited my mentors and they got on board from day one. Because of that, I started building those relationships and it was authentic. I mean, don't get me wrong, this wasn't like, you know, I'm trying to play anybody. I really care about what they had to say, and I incorporate all that feedback into my company to this day. So the other thing is, I make sure to go to everywhere, every webinar, every event, everything. My camera was always on, because most people, when they do their webinars, they don't even turn on their cameras, right? So I was very engaged. I was asking questions, I was getting involved with everything. Same thing with the Slack channel that we have for MedTech Innovator. I was helping people, I was sharing stuff. I was even offering to make introductions. I really made sure that people knew who I was. And I obviously also asked the MedTech Innovator people, the staff, for help, feedback, right? Am I doing this right? What do you think I should do? Anything that you can share with me that you think. I was very clear with them. I wanna go to the, I wanna get to the finals. I told them, and I remember they telling me, "Oh, Maria, about getting to the finals, it's so hard. It depends on the strategics and the sponsors." And I was like, " I'm gonna get there. What do you think I should do?" So I literally ask a lot of people how I needed to get there. And with the finals, the way how they pick the finalist, it's actually the mentors who go in front of the strategics, and they sort of champion your company. And they really went to bat for us. They told them how committed I was, the many people that from my team were actually going for participating to the winner because I brought people from my team... [00:32:45] Lindsey Dinneen: Yeah. [00:32:46] Maria Artunduaga: You know, very few founders did that. I brought people from Colombia, obviously online, people who barely could understand English. But, I made them prepare questions. "You need to do this and that we need to be super engaged. We need to help other people." And they saw it was hard work. And at the end, we got into the finals and what I realized was, okay, so after the finals, I understood that the game was, obviously it changed. The way how the winner is chosen is that the audience votes, right, during The MedTech Conference. So what I did was, I went all in on social media. We made an awesome video for the best video competition. I remember that that was the first thing that I did back in June. I scheduled two weeks. I flew to Columbia. I hired right people. I made sure that I was perfect, so I was part of the creative team. I designed everything. Again, I really like arts, right? That's why, one of the reasons why I didn't, I was in pleasantry and that's why I really like dancing too, right? So I'm obsessive with everything that we do. I really am into the details and I supervise everything. And we also got into the finals for the best video competition. So I was going to this problem from every single angle. I didn't let anything up to chance. I, yeah, I'm a freak. I'm a control freak. That's what I did. I remember that even for the pitch, the four and a half minute pitch, I practiced, I don't know how many hours, but every single thing that I say that was obviously memorized, needed to be perfect. The way how I, let's go back to dancing since you're a dancer yourself, the way how I moved my hands, right? The way, how I walked on that stage, everything was rehearsed. So, yeah, I mean, I just I worked my ass off. I mean, everything was the way it needed to be and that's how we won. [00:34:39] Lindsey Dinneen: Yeah. Wow. That's great. What a fantastic story. Yeah. Amazing. Yes. I love how it's so choreographed. Yeah, that's [00:34:48] Maria Artunduaga: great. It was choreographed, [00:34:50] Lindsey Dinneen: I love that. Excellent. Well, I know you have touched on the importance of legacy and how much that means to you, but how do you wish to be remembered after you leave this world? [00:35:03] Maria Artunduaga: Oh gosh. Yeah. I mean, so I have a little daughter, I want to some somehow replicate the same experience that I had with my mom. Maybe she doesn't even realize how much of the inspiration and the impact that she had on me. And again, leading by example, I don't spend a lot of hours with my daughter, right? I have a nanny for 12 hours. So my salary goes to her payment, right? Yeah, I wanna be remembered as somebody who tried very hard, who literally, instead of saying things, I walked the talk. The things that I said I was going to say. For example, I'm very opinionated with anything diversity and inclusion because, as I've said, I've experienced discrimination myself. So I walk the talk, I build a product, I build the change. I worked really hard. I impacted a lot of people. And more importantly, the world has changed somehow because I existed. So that's that. It's as simple as that. I wanna help other people get to fulfillment of their lives and their dreams. And yeah, and I obviously wanna be happy while I do all of these things. And more importantly, I wanna feel that I learned a lot. I really like learning. The process of learning every single day, learning a new thing makes me super happy. So if I don't learn something new, I consider day as, you know, as like a flop or something. So yeah, it's very simple. I'm actually a very simple person, I'm not that complicated. [00:36:30] Lindsey Dinneen: Yeah. Okay. And then final question. What is one thing that makes you smile every time you see or think about it? [00:36:39] Maria Artunduaga: Oh, cute. I mean, obviously my daughter. So I'm a mom. I'm 44, well, almost 45, and I had her at 42. So just thinking about her makes me smile every single time. She's a miracle baby. She's, you know, after four years of IVF, eight retrievals, it finally happened. I finally had her, and having her in my life has turned my world upside down in the best way. She's determined, and she's only three. She's diving into doing all sorts of things. She's doing gymnastics, she's building Legos, she's doing engineering stuff. I really like that "I can do anything attitude" and obviously I'm sort of like reinforcing her to do anything she wants to try. So seeing her try all these new things, all this confidence that I, that she has. It's like, I don't know. I mean, that inspires me. That motivates me to be a better mom, a better CEO, and to do exactly the same thing with the people that I work with. So everyone in my company, I I tell them I'm a mom, right? So, remember that, and I try to do the same with them. It's like I tell them, what do you wanna do? What do you wanna learn this month? What do you need? Right? My work as a CEO is getting the resources and put out the fires. Just tell me, and this is your playground, so I'm trying to do exactly the same with my daughter too. But yeah, I'm very happy with her. [00:38:07] Lindsey Dinneen: Aw, that's wonderful. I'm so glad. Well, oh my goodness, this conversation has been amazing. I kind of wish it didn't have to end, but I also wanna respect your time 'cause obviously you have so much going on. But thank you so much for sharing about your story, your advice. You're so inspiring, and I know this is gonna inspire so many people to go for it, and not to have the fear, to have that problem solving mentality, and growth mindset and learning and, hey, look where curiosity got you. [00:38:37] Maria Artunduaga: Yeah, exactly. That's a perfect slogan. It's all about that curiosity and it gets you places. Look at me. [00:38:43] Lindsey Dinneen: Yeah, exactly. Yeah. And this is just the start. [00:38:47] Maria Artunduaga: Yes, of course. [00:38:48] Lindsey Dinneen: Indeed. So I just wanna say thank you again for your time today, and we just wish you the most continued success as you work to change lives for a better world. [00:38:58] Maria Artunduaga: Thank you so much and thank you again for invitation. I really enjoyed it. [00:39:02] Lindsey Dinneen: Yeah, absolutely. Me too. And we are honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. We really appreciate you choosing that organization to support and thank you just again, so very much for your time here today. Yeah, and holy cannoli, thank you so much to our listeners for tuning in, and if you're feeling as inspired as I am right now, I'd love it if you'd share this episode with a colleague or two, and we'll catch you next time. [00:39:44] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

In this episode of, Dr. Sergio Zanotti explores the vital role of enteral nutrition in the ICU—a foundational element in the prevention and treatment of disease-related malnutrition among critically ill patients. He is joined by Dr. Leah Gramlich, a distinguished gastroenterologist and physician nutrition specialist from the Royal Alexandra Hospital in Alberta, Canada. Dr. Gramlich is a Professor of Medicine at the University of Alberta and the founding president of the Canadian Nutrition Society. She has also served on the Board of Directors for the American Society for Parenteral and Enteral Nutrition and chaired the Canadian Malnutrition Task Force, bringing deep expertise to this essential topic. Additional resources: Enteral Nutrition in Hospitalized Adults. Lead Gramlich, Peggi Guenter. New Engl J Med 2025: https://pubmed.ncbi.nlm.nih.gov/40239069/ Individualized nutritional support in medical inpatients at nutritional risk: a randomized clinical trial. The EFFORT Clinical Trial. Lancet 2019: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32776-4/abstract Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med 2023: https://pubmed.ncbi.nlm.nih.gov/36958363/ The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial. Lancet 2023: https://pubmed.ncbi.nlm.nih.gov/36708732/ Books mentioned in this episode: The Overstory: A Novel. By Richard Powers: https://bit.ly/43Drra1

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

- Introduction to the Broadcast and Song Premiere (0:10) - Song Lyrics and Philosophical Arguments (2:30) - Geopolitical Analysis and Land Grab (10:31) - Breakaway Civilization and Advanced Technology (32:29) - Economic and Strategic Importance of LA (41:19) - Conclusion and Call to Action (41:41) - Humanitarian Rights and Political Power (1:06:48) - Deportation as a Humanitarian Act (1:29:38) - Comparing Illegal Immigration to Trespassing (1:31:22) - The Impact of Illegal Immigration on American Society (1:35:22) - The Role of Compassion and Law in Deportation (1:36:47) - Emergency Preparedness and Satellite Communication (1:42:24) - The Importance of Communication in Emergencies (1:44:58) - The Growth of Starlink and Its Benefits (1:55:29) - Preparing for Natural Disasters and Conflicts (2:15:22) - Supporting American Businesses and Preparedness (2:20:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

In this episode of the DermSurgery Digest, you'll hear a summary of the cosmetic and general dermatology articles in the June 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Thomas Rohrer, MD, and Pooja Rambhia, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the surgical oncology and reconstruction articles in the June issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the June 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Christopher Arpey, MD, and Yesul Kim, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the June issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

At the 2025 American Society of Clinical Oncology Annual Meeting, Hope Rugo, MD, chaired a session on managing the side effects of new breast cancer treatments and also presented information on how to manage the side effects of hormonal therapy medicines, which are used to treat hormone receptor-positive breast cancer. Listen to the episode to hear Dr. Rugo explain: ways to manage the side effects of tamoxifen and the aromatase inhibitors why talking to your doctor about side is crucial to managing them her advice for people who are having side effects from hormonal therapy medicines

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Send us a textMike is at the 18th annual Ohio Stormwater Conference, where nearly 1,000 environmental professionals gather to discuss flooding, erosion, and water quality advances—and new challenges.The conversation begins with sobering news about watershed organizations facing an uncertain future as they scramble to fill funding gaps in their programs. We also talk with the Ohio Public Works Commission and its support of essential projects across the state. The latest Infrastructure Report Card from the American Society of Civil Engineers (ASCE) shows some improvement, but also notes the cost of neglecting funding for our shared assets.  What stands out at this conference is the personal connection between the professionals and their work. Their personal investment guides their technical expertise and inspires them to make a real-world impact with every project.Learn more about the Ohio Stormwater Conference at https://ohstormwaterconference.com/Sign up for the Sewer District's Summer Sprinkling Program at https://customerservice.neorsd.org/s/summer-sprinkling-program

Translational trends at this year's ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the findings from Executive Director of Biopharma Intelligence Lauren Martz's deep dive into first-in-human studies at the American Society of Clinical Oncology meeting, including how immunocytokines, solid tumor CAR Ts and Chinese innovation are thriving in early trials.The analysts also examine the signs of strain and resilience in biotech's crossover investors, as well as FDA's plans for revamping rare disease regulation. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656139#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:01 - Sponsor Message: ICON Biotech02:11 - ASCO's First-in-Human Trials12:46 - Crossover Investor Health Check22:54 - FDA's Rare Disease PlansTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Welcome to the Alan Smithee Podcast in which hosts Scott Simmons, Katie Hinsen & Michael Kammes talk about the latest news in production, post production, entertainment, tech and beyond. In this episode, the gang are joined by Beryl Shereshewsky, a successful YouTuber and former CNN producer, to explore the intricacies of content versus traditional media. There's a lively discussion centered around content creation, underscoring the evolving media landscape where traditional filmmaking intersects with modern digital content. And of course, there's a bunch of really cool things to get excited about. Special guest: Beryl Shereshewsky: https://www.beryl.nyc/Veo 3: https://gemini.google/overview/video-generation/Adobe price changes. It goes up if you want AI, goes down if you don't: https://www.provideocoalition.com/please-read-adobes-official-article-on-the-pricing-changes-coming-to-the-creative-cloud-plans/DaVinci Resolve 20 leaves beta, way before IBC: https://www.provideocoalition.com/davinci-resolve-20-released/American Society of Cinematographers Elects Mandy Walker, first woman, as President: https://theasc.com/news/american-society-of-cinematographers-elects-mandy-walker-as-presidentOne Cool Thing:Kaite: https://www.youtube.com/@OneSongPodcastMichael: Amaran t2c + 3" Baby Nail-On PlateScott:  https://wisprflow.ai/Beryl: Fluffy Cows - https://www.iowafarmbureau.com/Article/Iowas-fluffy-cows-go-viral-on-social-media

This week, we spoke with Rod Brunson about one of the most urgent and challenging topics in criminology: race and policing. Rod K. Brunson is a professor in the Department of Criminology and Criminal Justice at the University of Maryland, College Park. His tackles issues on police including community relations, youth violence, and evidence-based criminal justice policy. He has consistently called for effective crime reduction strategies that do not result in racially disparate treatment of minority citizens and disadvantaged neighborhoods. Rod is a fellow of the American Society of Criminology.

In today's episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Department of Surgery at Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts. In this discussion, Dr Mittendorf shared how ASCO is strategically preparing to address the long-term implications of proposed federal research funding cuts. She emphasized the significant return on investment generated by sustained NIH support, underscoring its role in fostering scientific innovation and stimulating the broader economy. She also advocated for structural reforms to be developed collaboratively with researchers, institutions, and policymakers to ensure continued progress in oncology is maintained, particularly in underfunded areas, such as prevention research. Dr Mittendorf also previewed her broader vision for ASCO, including expanding global collaboration and advancing equitable access to cancer care. She noted that these efforts will be complemented by continued emphasis on multidisciplinary care delivery and mentorship, which she discussed in more detail in part one of our conversation.

Did you know a daily weight loss pill might soon replace weekly injections for managing obesity? In this episode, I explore the exciting new development of a once-daily oral weight loss medication, oral semaglutide 50mg highlighting results from the OASIS 1 trial. With this, I explain how this pill could be a game-changer for people who are hesitant about injections like Wegovy or Zepbound. I break down how semaglutide works as a GLP-1 receptor agonist, the phases of drug development, and the impressive trial results showing an average 15% body weight loss in participants without diabetes. I also talk about common side effects, the FDA approval timeline, and what this could mean for patients looking for more accessible, convenient weight loss options. Curious about the future of weight loss treatments? Tune in to learn about a groundbreaking pill that could change everything.   Episode Highlight: Introduction of oral semaglutide 50mg as a potential weight loss pill  Explanation of how semaglutide works as a GLP-1 receptor agonist. Overview of the OASIS 1 phase 3 trial Breakdown of clinical trial phases and FDA approval process. Discussion of side effects Adherence rates and significant weight loss among participants. Insight into future FDA approval timelines and potential market release Importance of combining medication with lifestyle changes Considerations about insurance coverage and patient access   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

  We Welcome to Healthy Widow Healthy Woman Podcast, Guest Sharon Hanby-Robie, Interior Designer, residential home décor on-air expert for QVC network., showcasing the latest in interior design and home fashion to millions of television viewers. She's a member of American Society of Interior Designers (ASID). For more than thirty years, Sharon has been combining her unique ability to see and combine color, along with her aesthetic vision for simple elegance, to professionally help families create homes that are exceptionally beautiful as well as functional. She takes great care in listening to client's hearts as they express their personal ideas to help them realize their dreams. She is the author of many books including, The Simple Home: A Faith-filled Guide to Simplicity, Peace, and Joy in Your Home, My Name Isn't Martha, But I Can Decorate My home, and Decorating without Fear. Sharon's work has appeared numerous times on such highly-regarded television shows and networks such as The Today Show, HGTV, CBN, and DIY Network. Her newest endeavor is on her YouTube Channel “Safe Space with Sharon”.  Color Therapy & Healing Spaces with Sharon Hanby-Robie Sharon Hanby-Robie explores the transformative role color plays in the widow healing journey. Sharon reveals the deeply personal crisis that first connected her to the emotional impact of color, and how this awakening led to her groundbreaking "Safe Space with Sharon" approach to designing environments for those experiencing profound transitions and hoping to use color to better communicate themselves. The conversation delves into specific colors that can help widows navigate overwhelming emotions and identity disruption—from calming blues that reduce anxiety to grounding earth tones that provide stability during life's most turbulent transitions. Sharon shares evidence-based insights on how our visual environment directly impacts our psychological wellbeing when grief has disrupted our sense of home and self. Through touching client stories, Sharon illustrates how redesigning living spaces becomes a powerful metaphor for rebuilding life after loss. Hear the remarkable transformations. This episode offers practical wisdom for anyone seeking to create spaces that honor what was while supporting what can be.  

In this episode of the Meaning Project Podcast, Dr. Daniel A. Franz engages in a comprehensive discussion with Dr. Mark Hrymoc, a double board-certified psychiatrist specializing in addiction medicine. They explore the current landscape of addiction treatment, including the effectiveness of traditional methods like AA and the integration of modern medications. The conversation delves into the complexities of addiction, the role of genetics, and the emergence of behavioral addictions. They also discuss the impact of vaping, the potential of psychedelics in therapy, and the importance of destigmatizing mental health treatment.TakeawaysAddiction treatment is evolving with modern science.AA 12-step recovery remains foundational in addiction treatment.Listening to clients is crucial for effective treatment.Behavioral addictions are increasingly recognized and treated.Medications like naltrexone and Suboxone are game-changers.Genetics play a significant role in addiction susceptibility.Vaping poses new challenges in addiction treatment.Psychedelics show promise in treating mental health issues.Destigmatizing mental health treatment is essential for recovery.Long-term treatment may be necessary for chronic conditions.Dr. Hrymoc has extensive expertise in the psychopharmacology of addiction and other mental health disorders. He is double Board-certified in General Psychiatry and Addiction Psychiatry and was previously board-certified in Addiction Medicine. Dr. Hrymoc previously held the position of Assistant Clinical Professor of Psychiatry at UCLA, where he supervised training psychiatrists at their Addiction Psychiatry Clinic. He completed his subspecialist training in Addiction Psychiatry at Cedars-Sinai Medical Center in Los Angeles and currently serves as a consulting physician to several prestigious drug and alcohol treatment centers in the area.Dr. Hrymoc completed his psychiatric residency training at Harbor-UCLA Medical Center and also trained at UCLA Medical Center and the West Los Angeles Veterans Administration Hospital. He obtained an MD degree at Rutgers New Jersey Medical School and did his undergraduate studies at the University of Pennsylvania. He has worked in a variety of treatment settings, from non-profit community mental health clinics to federally-sponsored multi-site medication development studies.In addition to his clinical work, Dr. Hrymoc continues to be active in the local addiction treatment community. In September 2008, he founded Perspectives on Addiction, an interdisciplinary educational group for addiction professionals in Los Angeles. Dr. Hrymoc has served as the representative of the states of California, Alaska, and Hawaii to the American Academy of Addiction Psychiatry and was a member of the education committee of the California Society of Addiction Medicine. Dr. Hrymoc co-authored a chapter in Principles of Addiction Medicine, the main textbook of the American Society of Addiction Medicine and has been published in several academic journals.

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO. The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following: ·       Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781) o   Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).  o   An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas. o   With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]). ·       Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use o   Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma. o   Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. o   Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings. ·       Phase 1b/2 NEXICART-2 trial (NCT06097832) o   Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options. o   Among 12 patients who received the agent at 450 x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.  o   With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred. References 1. Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507 2. Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023 3. Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508

My guest today on the Online for Authors podcast is W. Terry Whalin, author of the book 10 Publishing Myths. W. Terry Whalin understands both sides of the editorial desk--as an editor and a writer. He worked as a magazine editor and his magazine work has appeared in more than 50 publications. A former literary agent, Terry is an Acquisitions Editor at Morgan James Publishing.   He has written more than 60 books through traditional publishers in a wide range of topics from children's books to biographies to co-authored books. Several of Terry's books have sold over 100,000 copies.   Terry's most recent book is BOOK PROPOSALS THAT SELL (THE REVISED EDITION) which has over 150 Five-Star reviews. He has also written 10 PUBLISHING MYTHS, INSIGHTS EVERY AUTHOR NEEDS TO SUCCEED and BILLY GRAHAM, A BIOGRAPHY OF AMERICA'S GREATEST EVANGELIST (all from Morgan James Publishing). Also, Terry has an innovative online training course to help authors effectively connect with literary agents and editors called Write a Book Proposal.   Terry is a popular speaker and teacher at numerous writers' conferences and an active member of the American Society of Journalists and Authors. He lives in Southern California and has an active following on twitter.   In my book review, I stated 10 Publishing Myths by W. Terry Whalin is a great craft book helping authors understand what publishing a book entails - and what it doesn't. Many writers get started on the path to authorship without a real understanding of what comes after the book is written. Terry's book gives authors a realistic look at what to expect.   I loved that the book gave real-life examples, actionable tips, and even links for more information. It's a quick read but stuffed with great information - whether you are published or not. This book should be on every author's bookshelf.   Subscribe to Online for Authors to learn about more great books! https://www.youtube.com/@onlineforauthors?sub_confirmation=1   Join the Novels N Latte Book Club community to discuss this and other books with like-minded readers: https://www.facebook.com/groups/3576519880426290   You can follow Author W. Terry Whalin Website: https://terrywhalin.blogspot.com/ X: @terrywhalin LinkedIn: @Terry Whalin FB: @terrywhalin   Purchase 10 Publishing Myths on Amazon: Paperback: https://amzn.to/3ZjpHka Ebook: https://amzn.to/3ZjpHka   Teri M Brown, Author and Podcast Host: https://www.terimbrown.com FB: @TeriMBrownAuthor IG: @terimbrown_author X: @terimbrown1   Want to be a guest on Online for Authors? Send Teri M Brown a message on PodMatch, here: https://www.podmatch.com/member/onlineforauthors   #wterrywhalin #10publishingmyths #authorcraft #writercraft #terimbrownauthor #authorpodcast #onlineforauthors #characterdriven #researchjunkie #awardwinningauthor #podcasthost #podcast #readerpodcast #bookpodcast #writerpodcast #author #books #goodreads #bookclub #fiction #writer #bookreview *As an Amazon Associate I earn from qualifying purchases.

Developer conference season is almost over, but we've got one show left to see: Apple's WWDC begins on Monday. Nilay, David, and Joanna Stern spend time going through both what they expect to see at the show, and why this year's WWDC might feel a bit different than in years past. Apple is in a tricky place with regulators, developers, and users alike, and has some genuine explaining to do. After that, they talk about the launch of the Nintendo Switch 2, and David's surprisingly easy adventure to acquire one. We also have a bit of smart glasses and AI gadgets news to discuss, so we do that too. Then it's time for Brendan Carr is a Dummy, and an update on a couple of the interesting new fediverse projects launching this week. Further reading: Verge subscriptions are on sale 40 percent off American Society of Magazine Editors Announces National Magazine Awards 2025 Winners Apple ordered to keep web links in the App Store  Payment companies team up to help developers ditch App Store billing Apple could be adding camera controls and sleep detection to your AirPods Switch 2 launch: where to find restocks online and in-store  Look inside the Nintendo Switch 2 with the console's first teardown  Mario Kart World's designers had to rethink everything to make it open world  Nintendo is updating even more games for the Switch 2 Here's what's inside Meta's experimental new smart glasses  Meta's reportedly shopping for exclusive content on its upcoming VR headset  Meta reportedly sidelined ‘Quest 4' designs for a goggles-like mixed-reality headset  FCC investigation looms over EchoStar's missed interest payments and a new satellite  From Ars Technica: FCC Republican resigns, leaving agency with just two commissioners Jony Ive's OpenAI device gets the Laurene Powell Jobs nod of approval  ChatGPT's goal is to be a ‘super assistant' for every part of your life  Email us at vergecast@theverge.com or call us at 866-VERGE11, we love hearing from you. Help us plan for the future of The Vergecast by filling out a brief survey: voxmedia.com/survey. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower. Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell carcinoma. Plus, the team compares notes from the ASCO exhibit hall. To learn more about the topics in this episode: ASCO: AstraZeneca, Daiichi flex Enhertu's muscles in first-line breast cancer as they drop new phase 3 gastric cancer data 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race ASCO: J&J highlights Rybrevant-Lazcluze combo in 'Breathtaking Moments' lung cancer campaign high over Chicago skyline See omnystudio.com/listener for privacy information.

Dive into Episode #146 of the Psych Health and Safety USA Podcast, featuring host Dr. I. David Daniels, PhD, CSD, VPS, and special guest Monique Parker, 2025 Senior Vice President of the American Society of Safety Professionals (ASSP) talks about her career as a safety professional, her ascension to President of the ASSP in 2026 and the future of the safety profession, including her view regarding the importance that psychological health and safety will play. The American Society of Safety Professionals (ASSP) was founded on March 25, 1911. It was initially established as the United Association of Casualty Inspectors in response to the Triangle Shirtwaist Factory fire, a tragic workplace disaster that killed 146 garment workers. The organization later changed its name to the American Society of Safety Engineers (ASSE) in 1914. Then, it adopted its current name in 2018 to reflect the evolving nature of the safety profession. After over twenty years in the safety profession, Ms. Parker will be become the 11th woman in the history of the ASSP and the first black woman to serve as president of the society.

Ronnie Rose is a research scientist and rising science communicator, sister in Christ, and a dear friend of mine! Ronnie has contributed to research at two of the world's leading cancer hospitals and over the years, her work has contributed to studies on bladder, lung, prostate, and most recently, breast cancer. She's also co-authored an educational textbook published by the American Society of Clinical Oncology, addressing the rising cost of cancer drugs and how it impacts patient access — a topic that speaks directly to her mission. Ronnie's built a diverse background from lab work in neuroscience to ecology — experience that now helps her connect ideas across disciplines and fuels her bigger mission: to make science accessible to underrepresented communities think about their health, and empower them with knowledge.@ronnierose.nyc ronnierose.nyc

Sean Tipton is Chief Advocacy and Policy Officer for the American Society for Reproductive Medicine. We'll discuss a new(ish) movement called "Ethical IVF" which is an intentionally nice-sounding misnomer of a move that aims to make IVF much more difficult and expensive.Executive Team | American Society for Reproductive Medicine | ASRMASRM Center for Policy & Leadership Releases Fact Sheet on Misleading Terminology, “Restorative Reproductive Medicine” and "Ethical IVF" | American Society for Reproductive Medicine | ASRM

Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Change is inevitable in business, which is why change management is a key skill set for admins and EAs to master. In this episode, we discuss the change curve, emotional regulation, and the importance of building relationships to implement change initiatives. Recorded at EA Ignite Fall 2024 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Drs. Jensen and Richey welcome Dr. Andrew Belis to Dean's chat! A leader in the profession, Dr. Belis has worked in with an orthopedic practice in Florida and is has been the Fellowship Director for the Orhopedic Center of Florida's Foot and Ankle Surgery Fellowship since 2017 in Fort Myers, FL.    Dr. Belis has served in many roles with the Florida Podiaric Medical Association, including President.  He is also the past Chairman of the Board for the American Society of Podiatric Surgeons (ASPM). Dr. Belis earned his Bachelor of Science in Physiology at Boston University  and went on to complete his Doctorate of Podiatric Medicine at Temple University. He completed 3 years of residency training at Wycoff Heights Residency Program and Greater Baltimore Hospital.    Tune in for a great discussion on Fellowships, surgical training, the current state of podiatric practice, and the future of our prrofession!  Enjoy! https://bakodx.com/ https://bmef.org/ www.explorepodmed.org https://podiatrist2be.com/

Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed payments across two deals. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the takeout of Blueprint Medicines for $9.1 billion up front gives Sanofi a drug for a rare immunological disorder and bolsters the French pharma's already strong presence in immunology. The analysts also assess the $3.5 billion partnership between BioNTech and Bristol Myers Squibb for an asset targeting cancer's hottest target, PD-(L)1 x VEGF, and underwhelming data from the leading asset against the target, PD-1 x VEGF bispecific ivonescimab, from Summit and Akeso Inc. Those data coincided with the kick-off of the American Society of Clinical Oncology (ASCO) meeting in Chicago, where almost a dozen companies were presenting readouts for another hot target, CLDN18.2. Evopoint is among the companies; its program recently attracted Astellas as a partner. Meanwhile, the biopharma industry is racing to counter the White House's most favored nation drug pricing strategy. BioCentury's Washington analyst, Steve Usdin, explains the urgency and details some of industry's options.View full story: https://www.biocentury.com/article/656097#biotech #biopharma #pharma #lifescience #deals00:00 - Introduction04:39 - Sanofi Buys Blueprint09:22 - BMS-BioNTech20:01 - Hot Targets23:40 - Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Fumiko Chino, MD, summarized her presentation on how doctors can help the people they care for overcome financial issues. She also offered some strategies for patients. Listen to the podcast to hear Dr. Chino explain: some specific resources for people with cancer why people with breast cancer may have the most financial issues her top three recommendations for people having financial hardship

In this episode of Voices of Otolaryngology, Rahul K. Shah, MD, MBA, AAO-HNS/F EVP/CEO, talks with Vince Loffredo, EdD, Chief Learning Officer at the American Society for Anesthesiology, about the future of medical education, providing advice to lecturers on how to engage audiences. They discuss how technology has accelerated changes in medical learning, moving from traditional lectures toward micro-learning, interactive formats, and personalized education. Dr. Loffredo shares insights on engaging learners through gamification, virtual reality, social media platforms, and continuous educational experiences, emphasizing collaborative, team-based learning across specialties.  Helpful Resources: Otolaryngology Core Curriculum (OCC): https://www.entnet.org/occ  More Ways to Listen: Spotify: https://open.spotify.com/show/3UeVLtFdLHDnWnULUPoiin  Apple Podcasts: https://podcasts.apple.com/us/podcast/voice-of-otolaryngology/id1506655333   Connect the AAO-HNS: Instagram: https://www.instagram.com/aaohns  X (Twitter): https://x.com/AAOHNS  Facebook: https://www.facebook.com/AAOHNS  LinkedIn: https://www.linkedin.com/company/american-academy-of-otolaryngology/  Website: https://www.entnet.org  Shop AAO-HNS Merchandise: https://www.otostore.org  This episode is sponsored by Inspire Medical Systems - For more information and medical education resources, visit: https://bit.ly/InspireAAO Help Us Improve Future Episodes: Share your feedback and topic suggestions at https://forms.office.com/r/0XpA83XNBQ  Subscribe to Voices of Otolaryngology for more insights from leading voices in ENT. New episodes released every Tuesday.

In this powerful and emotional episode, we welcome special guest Jen, who bravely shares the story of her husband Mike's eight-year battle with brain cancer—a journey marked by resilience, heartbreak, and unwavering love.Through years of surgeries, research, second opinions, and clinical trials, Jen and Mike did everything they could to fight the disease. In the midst of the uncertainty, they were gifted with a beautiful daughter, who became a beacon of hope and strength.Eventually, when there options were available exhausted, they made the courageous choice to shift from fighting the disease to fully living the time they had left together. Jen opens up about what it means to love deeply, grieve honestly, and honor someone's life by continuing to move forward.This is a story of grace in the face of pain, and what it means to truly live—even when time is limited.Follow us on IG for more:https://www.instagram.com/spillinitpodcast?igsh=MWM1ZTZncDBiczZ4Mg%3D%3D&utm_source=qrhttps://www.instagram.com/thecortreport?igsh=NWxsaDdkOXRhbm56&utm_source=qrhttps://www.instagram.com/grayed_early?igsh=MWRwZ2VodzRmaHZuNA%3D%3D&utm_source=qrhttps://www.instagram.com/jena0614?igsh=Y2JoanphM2ZzbmFpHave an inspiring story you would like to share? Fill out the following Questionnaire and we will be in touch.Resources:

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Katie Schmitz chaired a session on ways to ensure that exercise is part of every cancer treatment plan. She also talked about how results of the CHALLENGE trial in colon cancer might apply to breast cancer. Listen to the episode to hear Dr. Schmitz explain: strategies doctors can use to make exercise an integral part of cancer care how people can afford and stay motivated to exercise the results of the CHALLENGE trial, which found that three years of exercise after colon cancer treatment improved disease-free survival (how long people lived without the cancer coming back) and overall survival (how long people lived whether or not the cancer came back)

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky discuss: The SERENA-6 trial, which found that if metastatic hormone receptor-positive, HER2-negative breast cancer develops ESR1 mutations during first hormonal therapy treatment, switching to camizestrant from an aromatase inhibitor before the cancer grows improves outcomes. Results from the DESTINY-Breast09 trial showing that the combination of Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Perjeta (chemical name: pertuzumab) is a better first treatment for metastatic HER2-positive breast cancer than the current standard of THP chemo.  The ASCENT-04/KEYNOTE-D19 trial, which found that people with metastatic, PD-L1-positive, triple-negative breast cancer fared better with the combo of Trodelvy (chemical name: sacituzumab govitecan-hziy) and Keytruda (chemical name: pembrolizumab) as a first treatment compared to people who received chemotherapy and Keytruda.

Rebecca Danigelis is the British 80-year-old star of the critically acclaimed and award-nominated documentary Duty Free. After being fired from her long-time career as a hotel housekeeper at the age of 75, Rebecca has become an activist against ageism in both workplaces and communities. The upbeat mother of three uses her lived experience to educate employers and employees on the values of being age-inclusive, underlining the essentiality of including age in DEI initiatives. She also stresses the importance of family. As a speaker, Rebecca has the ability to connect with audiences internationally. It is her joy and mission to help others.Since Duty Free's premiere, she has inspired thousands via notable live discussions with organizations including AARP, World Health Organization, National Council on Aging, SouthArts, American Society on Aging, Cirkel and more. She speaks at schools and recently was invited to speak about ageism at the United Nations. She is being featured in The New York Times for the second time in April.Rebecca has gone skydiving in this chapter in her life, and continues to live an exciting, vital life in New York City. She continues to face life with optimism, despite a cancer diagnosis and other challenges.Learn more and watch the film:https://www.dutyfreefilm.com/@dutyfreefilm or @rebrexithttps://www.facebook.com/DutyFreeFilm/https://www.instagram.com/dutyfreefilm/

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics: Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00) Updated data with belantamab mafodotin for the management of MM (12:39) Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52) ASH 2024 updates with other novel agents and strategies for the management of MM (21:32) CME information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics: Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00) Sequencing bispecific antibodies and CAR T-cell therapy (10:40) Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03) Optimizing maintenance therapy for patients with MM (31:11) Novel management strategies for smoldering myeloma (36:29) Role of anti-CD38 antibodies in the up-front management of MM (41:41) Available data with cereblon E3 ligase modulatory drugs for MM (47:45) CME information and select publications